Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc.

Merck Sharpe & Dohme Corp.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Roger John Snow

Daniel R Goldberg

Hidenori Takahashi

Tina Marie Morwick

Thomas Martin Kirrane, Jr

Anthony S Prokopowicz

Donghong Amy Gao

Neil Moss

Abdelhakim Hammach

Michael Robert Turner

Robert Sibley

Ronald John Sorcek

Yunlong Zhang

Daniel Richard Marshall

Lana Louise Smith Keenan

Alexander Heim-Riether

Asitha Abeywardane

Frank Wu

Weimin Liu

Todd Bosanac

Daniel Kuzmich

Mario G Cardozo

Derek Cogan

Christopher Ronald Sarko

Charles Lawrence Cywin

Erick Richard Roush Young

Usha R Patel

Xiao-Jun Wang

John David Ginn

Jiang-Ping Wu

Matt Aaron Tschantz

Craig Andrew Miller

Xin Guo

Wang Mao

Fariba Soleymanzadeh

Sabine K Schlyer

Gregory Paul Roth

Stephen James Boyer

Philip Dean Ramsden

Steven S Pullen

Erick Richard Young

Robert D Selliah

Eugene Richard Hickey

Cheng-Kon Shih

Yu Yang

Eugene R Hickey

Raymond Baker

Georg Dahmann

Renee M Zindell

Karl D Hargrave

Hossein Razavi

Graham A Showell

Yancey David Ward

Lei Qiao

Zhaoming Xiong

Michael Jason Burke

Alan David Swinamer

Peter Allen Nemoto

Ho Yin Lo

Michael Peter Winters

Anil Kumar Padyana

Brian Nicholas Cook

Qiang Zhang

Xiang Li

John Saunders

Steven Richard Brunette

Ingo Andreas Mugge

Joerg Bentzien

Ji Wang

Jennifer Burke

Chuk Chui Man

Steven John Taylor

Roman Wolfgang Fleck

Denise Andersen

Clara K Miao

Yang Yu

Kevin J Moriarty

Kaka Dey

Noel Stewart Wilson

Jinbo Lee

Thomas P Parks

Ian F Potocki

Younggi Choi

John Edward Mangette

Thomas Martin Kirrane

Thomas Martin Kirrane Jr

Michael Jason Bruke

Jr Thomas Martin Kirrane

Criag Andrew Miller

John E Mangette

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Rho kinase inhibitors

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, A, Land B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Inhibitors of leukotriene production

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

Heterocyclic compounds containing an indole core

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R, R, R, R, Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, Rand X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed is a compound of formula (I). Wherein R, RAr and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10. 

[object Object]

Isoquinolinone Rho kinase inhibitors

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R, R, R. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10. 

2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10

The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein Rto R, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

CCR10 antagonists

Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases.

Anti-cytokine heterocyclic compounds

Disclosed are substituted benzimidazole compounds of formula (I): wherein R, R, R, Rand Xare defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

Substituted benzimidazole compounds

Disclosed are novel compounds of formula (I):wherein Ar, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

Heterocyclic compounds useful as inhibitors of tyrosine kinases

Growing community of inventors

Danbury, CT, United States of America

Roger John Snow